

МІНІСТЕРСТВО ОХОРОНИ ЗДОРОВ'Я УКРАЇНИ
НАЦІОНАЛЬНИЙ ФАРМАЦЕВТИЧНИЙ УНІВЕРСИТЕТ
КАФЕДРА ПРОМИСЛОВОЇ ТЕХНОЛОГІЇ ЛІКІВ ТА КОСМЕТИЧНИХ ЗАСОБІВ
КАФЕДРА АПТЕЧНОЇ ТЕХНОЛОГІЇ ЛІКІВ

MINISTRY OF HEALTH OF UKRAINE
NATIONAL UNIVERSITY OF PHARMACY
DEPARTMENT OF INDUSTRIAL TECHNOLOGY OF MEDICINES AND COSMETICS
DEPARTMENT OF DRUG TECHNOLOGY



Матеріали
V міжнародної науково-практичної конференції
Proceedings of the V International Scientific and Practical Conference

ФУНДАМЕНТАЛЬНІ ТА ПРИКЛАДНІ ДОСЛІДЖЕННЯ
У ГАЛУЗІ ФАРМАЦЕВТИЧНОЇ ТЕХНОЛОГІЇ

FUNDAMENTAL AND APPLIED RESEARCH IN THE
FIELD OF PHARMACEUTICAL TECHNOLOGY

23 жовтня 2025 р.
October 23, 2025
Харків, Україна
Kharkiv, Ukraine

RELEVANCE OF THE DEVELOPMENT OF HARD GELATIN CAPSULES FOR THE TREATMENT OF RAYNAUD'S SYNDROME

Slizkova D. S., Kryklyva I. O., Sichkar A. A.

National University of Pharmacy, Kharkiv, Ukraine

Introduction. Raynaud's syndrome (RS) is episodes of transient digital ischemia due to vasospasm of digital arteries, precapillary arterioles and cutaneous arteriovenous shunts under the influence of cold temperature and emotional stress. The clinical significance of RS is due to its high prevalence in the population and frequent association with other, often life-threatening, diseases and conditions. RS occurs in 3-5% of the population, most often manifesting itself at the age of 20-40 years, especially in women, who are 2-9 times more likely to suffer than men. In the elderly (over 60 years of age), the prevalence is much lower (0.1-1%). The primary syndrome, as an independent disease, accounts for more than 80 % of cases, while the secondary syndrome is a complication of other pathologies and occurs in 20 % of cases. Raynaud's syndrome develops against the background of other diseases or external factors and can lead to more serious complications (for example, ulcers on the fingers, gangrene).

Purpose of the study. Justification of the choice of active pharmaceutical ingredients in the composition of hard gelatin capsules for the treatment of Raynaud's syndrome.

Research methods. Analysis and generalization of scientific literature data.

Main results. As active pharmaceutical ingredients, we selected nicotinic acid and dry extracts of ginger and ginkgo biloba. Nicotinic acid has a vasodilating effect at the level of prearterioles and arterioles, as a result of which microcirculation improves. It has a weak anticoagulant effect, has detoxification properties due to the enhancement of the detoxification function of the liver and kidneys. Dry ginger extract promotes vasodilation, improves blood circulation and has an anti-inflammatory effect. Dry ginkgo biloba extract improves blood circulation in the fingertips, therefore it is offered as a remedy for the treatment of Raynaud's syndrome. The optimal dosage form for the treatment of Raynaud's syndrome is hard gelatin capsules. They provide accurate dosing of active pharmaceutical ingredients, which is important for achieving a stable therapeutic effect and reducing the risk of overdose. Medicinal products in capsule form contribute to the gradual release of active substances, which prolongs the effect of the drug and improves mucosal protection.

Conclusions. Based on the analysis of scientific literature sources, the feasibility of using nicotinic acid and dry extracts of ginger and ginkgo biloba for the treatment of Raynaud's syndrome has been shown.